AZ/Daiichi Sankyo’s Enhertu gets second US cancer indicationAstraZeneca and Daiichi Sankyo’s Enhertu cancer drug has picked up a second indication, in patients who have stomach Share XAZ/Daiichi Sankyo’s Enhertu gets second US cancer indicationhttps://pharmaphorum.com/news/az-daiichi-sankyos-enhertu-gets-second-us-cancer-indication/
J&J single-shot COVID-19 vaccine shows early promiseJ&J has announced early trial results that suggest its single-shot coronavirus vaccine provides a sustained response against the Share XJ&J single-shot COVID-19 vaccine shows early promisehttps://pharmaphorum.com/news/early-data-backs-jjs-single-shot-coronavirus-vaccine-phase-3-results-due-soon/
EMA says AstraZeneca’s COVID-19 shot could be approved on 29 JanuaryThe European medicines Agency (EMA) said this morning it has received a marketing application from AstraZeneca for its Share XEMA says AstraZeneca’s COVID-19 shot could be approved on 29 Januaryhttps://pharmaphorum.com/news/ema-says-astrazenecas-covid-19-shot-could-be-approved-on-29-january/
Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelBoehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as Share XBoehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelhttps://pharmaphorum.com/news/boehringer-lillys-jardiance-ties-to-match-azs-farxiga-with-heart-failure-label/
Resourceful or risky? The UK’s controversial COVID-19 vaccine strategyAs COVID-19 vaccines are hastily deployed in the UK for priority groups, a debate rages over the government’s Share XResourceful or risky? The UK’s controversial COVID-19 vaccine strategyhttps://pharmaphorum.com/r-d/views-analysis-r-d/resourceful-or-risky-the-uks-controversial-covid-19-vaccine-strategy/
UK left trailing as EU quickly approves Moderna’s COVID-19 vaccineThe European Union has approved the coronavirus vaccine from Moderna, leaving the UK trailing because of changes to Share XUK left trailing as EU quickly approves Moderna’s COVID-19 vaccinehttps://pharmaphorum.com/news/uk-left-trailing-as-eu-quickly-approves-modernas-covid-19-vaccine/
UK promises ‘uplift’ in COVID-19 vaccinations as crisis deepensThe UK government has promised a “massive uplift” in the number of coronavirus vaccinations carried out this week, Share XUK promises ‘uplift’ in COVID-19 vaccinations as crisis deepenshttps://pharmaphorum.com/news/uk-promises-uplift-in-covid-vaccinations-as-crisis-deepens/
FDA and doctors warn against extending COVID-19 vaccine dose gapTinkering with the dosing schedule of COVID-19 vaccines runs a “significant risk” to public health, the FDA has Share XFDA and doctors warn against extending COVID-19 vaccine dose gaphttps://pharmaphorum.com/news/fda-and-doctors-warn-against-extending-covid-19-vaccine-dose/
AZ closes $400 million Atacand sale to Germany’s CheplapharmAstraZeneca has completed the sell-off of another mature product, hiving off its Atacand cardiovascular franchise to Cheplapharm as Share XAZ closes $400 million Atacand sale to Germany’s Cheplapharmhttps://pharmaphorum.com/news/az-closes-400-million-atacand-sale-to-germanys-cheplapharm/
